Shandong Keyuan Pharmaceutical (301281.SZ): Two products are expected to be selected in the national centralized drug procurement.
Koyuan Pharmaceutical (301281.SZ) announced that its subsidiary, Linuo Pharmaceutical, participated in the bidding for the 12th batch of national centralized purchasing of pharmaceuticals. According to the Proposed Selection Results Announcement for the 12th Batch of National Centralized Pharmaceutical Purchasing issued by the National Organization for Medicines Unified Procurement Office (hereinafter referred to as the Unified Procurement Office), Linuo Pharmaceutical's products are proposed for selection in this centralized procurement. The proposed selected products are: injectable isavuconazole and betahistine hydrochloride tablets.
Shandong Keyuan Pharmaceutical (301281.SZ) announced that its subsidiary, Lino Pharmaceutical, participated in the bidding for the 12th batch of national organization drug centralized procurement. According to the public announcement of the proposed selection results for the 12th batch of national organization drug centralized procurement issued by the National Organization Drug Joint Procurement Office (hereinafter referred to as the "Joint Procurement Office"), Lino Pharmaceutical's products are proposed to be selected for this centralized procurement. The products proposed for selection are: injectable isavuconazonium sulfate and hydrochloride betamethasone tablets.
Related Articles
DEFENG SOLIFE (08403) has entered into a cooperation agreement with Beijing Central Good Goods.
Jitai Technology (07666) AI formulation innovation platform launched at Jiangsu Hengrui Pharmaceuticals to accelerate NanoForge commercialization.
LEE & MAN PAPER (02314) will distribute an interim dividend of HKD 0.112 per share on September 3.
DEFENG SOLIFE (08403) has entered into a cooperation agreement with Beijing Central Good Goods.
Jitai Technology (07666) AI formulation innovation platform launched at Jiangsu Hengrui Pharmaceuticals to accelerate NanoForge commercialization.
LEE & MAN PAPER (02314) will distribute an interim dividend of HKD 0.112 per share on September 3.
RECOMMEND
